CN103830453A - Traditional Chinese medicine composition and traditional Chinese medicine preparation for treating central serous chorioretinopathy - Google Patents
Traditional Chinese medicine composition and traditional Chinese medicine preparation for treating central serous chorioretinopathy Download PDFInfo
- Publication number
- CN103830453A CN103830453A CN201410098468.9A CN201410098468A CN103830453A CN 103830453 A CN103830453 A CN 103830453A CN 201410098468 A CN201410098468 A CN 201410098468A CN 103830453 A CN103830453 A CN 103830453A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- radix
- grams
- medicine composition
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 96
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 208000003569 Central serous chorioretinopathy Diseases 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 239000000284 extract Substances 0.000 claims abstract description 7
- 239000009636 Huang Qi Substances 0.000 claims description 15
- 241000756943 Codonopsis Species 0.000 claims description 14
- 241000222640 Polyporus Species 0.000 claims description 14
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 14
- 210000000582 semen Anatomy 0.000 claims description 14
- 239000002671 adjuvant Substances 0.000 claims description 11
- 239000004375 Dextrin Substances 0.000 claims description 6
- 229920001353 Dextrin Polymers 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- 235000019425 dextrin Nutrition 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 230000004438 eyesight Effects 0.000 abstract description 9
- 230000008901 benefit Effects 0.000 abstract description 4
- 230000036407 pain Effects 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 241000758794 Asarum Species 0.000 abstract 1
- 241001061264 Astragalus Species 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000003805 Musa ABB Group Nutrition 0.000 abstract 1
- 240000008790 Musa x paradisiaca Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 235000015266 Plantago major Nutrition 0.000 abstract 1
- 244000171085 Polyporus umbellatus Species 0.000 abstract 1
- 235000004837 Polyporus umbellatus Nutrition 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 210000004233 talus Anatomy 0.000 abstract 1
- 208000004880 Polyuria Diseases 0.000 description 22
- 239000008280 blood Substances 0.000 description 20
- 230000035619 diuresis Effects 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 19
- 229940079593 drug Drugs 0.000 description 19
- 206010030113 Oedema Diseases 0.000 description 17
- 210000001525 retina Anatomy 0.000 description 16
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000001939 inductive effect Effects 0.000 description 8
- 230000001882 diuretic effect Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 230000002984 haematinic effect Effects 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 241000521257 Hydrops Species 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 239000002934 diuretic Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000036737 immune function Effects 0.000 description 5
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 5
- 229960004793 sucrose Drugs 0.000 description 5
- 206010025421 Macule Diseases 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000036592 analgesia Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 208000037920 primary disease Diseases 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010047513 Vision blurred Diseases 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000002223 anti-pathogen Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 208000029257 vision disease Diseases 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 241001481828 Glyptocephalus cynoglossus Species 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010063341 Metamorphopsia Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 230000006578 abscission Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000000162 simple eye Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicine for treating eye diseases, and in particular relates to a traditional Chinese medicine composition and a traditional Chinese medicine preparation for treating central serous chorioretinopathy. The traditional Chinese medicine composition is mainly prepared from the following raw materials: 9-12 grams of pilose asiabell root, 9-12 grams of astragalus, 9-12 grams of bighead atractylodes rhizome, 2-3 grams of liquorice, 9-12 grams of prepared rehmannia root, 9-12 grams of angelica sinensis, 9-12 grams of red peony root, 9-12 grams of polyporus umbellatus, 9-12 grams of poria cocos, 9-12 grams of rhizoma alismatis, 9-12 grams of plantain seed, 9-12 grams of cassia twig and 3-6 grams of asarum. The traditional Chinese medicine preparation comprises an active ingredient and a pharmaceutically-acceptable excipient, wherein the active ingredient is the traditional Chinese medicine composition or an extract of the traditional Chinese medicine composition. The traditional Chinese medicine composition and the traditional Chinese medicine preparation for treating the central serous chorioretinopathy have the advantages that the treatment cycle can be obviously shortened; eyesight of patients is rapidly recovered; the pain of the patients is relieved; the occurrence of other complications is reduced.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of ophthalmic diseases, relate in particular to a kind of Chinese medicine composition and Chinese medicine preparation that is used for the treatment of central serous chorioretinopathy.
Background technology
Central serous chorioretinopathy is because retinal pigment epithelium (RPE) barrier function is not normal, form the shallow disengaging of macula area neuroepithelium of retina, be more common in the male adults of 20～45 years old, men and women's ratio is 7～10:1, mostly be simple eye morbidity, it is 7%～13% that eyes are sent out patient, has generally acknowledged that at present primary disease is due to due to the barrier function damage of RPE cell.Sealing small band between RPE cell be between retina and choroid together with barrier, once sealing small band suffers damage, the barrier function of RPE cell is damaged, the effusion of choriocapillary enters under neuroepithelium of retina and accumulates through this damaged area, thereby causes neurepithelial serous detachment.
Patient's subjective symptoms has metamorphopsia, diminishes, color is looked, muscae genetic vision, slight visual deterioration.Primary disease has tendency of recurrence, and course of disease length or multiple relapse person can cause permanent visual disorder.The visible macula area of ophthalmologic examination has the shallow abscission zone of plate-like slurry retina of 1～3PD size, has reflective swooning around, and foveal reflex disappears.
Primary disease is often brought out by psychentonia and the factor such as overtired, and the normal method that adopts dehydration and enhancing human body immunity power is treated now, and its treatment cycle is long, and vision restoration produces complication slowly and easily.
Summary of the invention
Technical problem to be solved by this invention is: the deficiency existing for prior art, a kind for the treatment of cycle that shortens is provided, improve vision, reduce the Chinese medicine composition that is used for the treatment of central serous chorioretinopathy of complication, and the Chinese medicine preparation that uses described Chinese medicine composition to prepare.
For solving the problems of the technologies described above, technical scheme of the present invention is:
Be used for the treatment of the Chinese medicine composition of central serous chorioretinopathy, described Chinese medicine composition is mainly made up of following raw material: Radix Codonopsis 9～12g, the Radix Astragali 9～12g, the Rhizoma Atractylodis Macrocephalae 9～12g, Radix Rehmanniae Preparata 9～12g, Radix Angelicae Sinensis 9～12g, Radix Paeoniae Rubra 9～12g, Polyporus 9～12g, Poria 9～12g, Rhizoma Alismatis 9～12g, Semen Plantaginis 9～12g, Ramulus Cinnamomi 9～12g and Herba Asari 3～6g.
Improve as one, described Chinese medicine composition is mainly made up of following raw material: Radix Codonopsis 9～12g, the Radix Astragali 9～12g, the Rhizoma Atractylodis Macrocephalae 9～12g, Radix Glycyrrhizae 2～3g, Radix Rehmanniae Preparata 9～12g, Radix Angelicae Sinensis 9～12g, Radix Paeoniae Rubra 9～12g, Polyporus 9～12g, Poria 9～12g, Rhizoma Alismatis 9～12g, Semen Plantaginis 9～12g, Ramulus Cinnamomi 9～12g, Herba Asari 3～6g and Radix Glycyrrhizae 2～3g.
Preferably, described Chinese medicine composition is mainly made up of following raw material: Radix Codonopsis 10g, Radix Astragali 10g, Rhizoma Atractylodis Macrocephalae 10g, Radix Rehmanniae Preparata 10g, Radix Angelicae Sinensis 10g, Radix Paeoniae Rubra 10g, Polyporus 10g, Poria 10g, Rhizoma Alismatis 10g, Semen Plantaginis 10g, Ramulus Cinnamomi 10g, Herba Asari 4g and Radix Glycyrrhizae 3g.
The pharmacology that the present invention is used for the treatment of each raw material in the Chinese medicine composition of central serous chorioretinopathy is:
Radix Codonopsis (Qi-tonifying drug): invigorating the spleen and replenishing QI, enriching blood and promoting secretion of body fluid, can enrich blood and can QI invigorating, has the function of antioxidation, enhancing immunity.
The Radix Astragali (Qi-tonifying drug): spleen invigorating invigorating middle warmer, ascending up spleen-Qi and Yang, benefit is defended consolidating superficial resistance, diuresis, promoting pus discharge and tissue regeneration strengthening, wind dispelling fortune poison, inducing diuresis to remove edema, has resisting fatigue, defying age, antioxidation, radioprotective, can strengthen and regulate body's immunity, interferon system is had to facilitation, can improve the premunition of body.
The Rhizoma Atractylodis Macrocephalae (Qi-tonifying drug): invigorating the spleen and benefiting QI, dampness diuresis, with the benefit such as the Radix Astragali, Radix Saposhnikoviae strengthening spleen and lung, the product compatibility that dispels the wind, imperial evil with consolidating superficial resistance, promote cellular immune function, there are diuresis, calmness, antitumor action.
Radix Glycyrrhizae (Qi-tonifying drug): invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, coordinating the actions of various ingredients in a prescription.
Radix Angelicae Sinensis (hematonic): tonifying blood and regulating menstruation, promoting blood circulation and stopping pain, energy and blood are enriched blood, and broken stagnant blood is supported fresh blood, and blood circulation promoting increases blood flow.
Radix Rehmanniae Preparata (hematonic): the yin nourishing of enriching blood, life essence-filling, marrow-benefitting, promoting blood circulation, sharp knowledge, the beneficial painstaking effort of energy, improve renal function.
Radix Paeoniae Rubra (hematonic): promoting blood circulation to remove blood stasis, loose strange blood, lets out clearly liver-fire, cures mainly heat in blood, blood stasis, and energy clearing away heat and cooling blood makes the cellular immune function of low state recover normal.
Ramulus Cinnamomi (diaphoretic medicine, wind-cold-dispersing medicinal): diaphoresis expelling pathogenic factors from muscles, promoting the flow of QI-blood by warming the meridian, supporing yang activating QI, has stomach invigorating, diuresis, analgesia, calmness, anticonvulsant action.
Herba Asari (diaphoretic medicine, wind-cold-dispersing medicinal): the cold expelling that induces sweat, wind-expelling pain-stopping, sensible, warming the lung to resolve fluid-retention, has antipyretic, antiinflammatory, calmness, anticonvulsant action.
Poria (edema-alleviating diuretic): inducing diuresis to remove edema, eliminating dampness by diuresis, spleen invigorating, mind calming, the property of medicine is gentle, both can be eliminating evil, again can righting, diuretic and do not hinder healthy energy, real be the key medicine of inducing diuresis to remove edema, treats the edema due to retention of water-damp in the body.Pharmacology has the effect of diuresis, calmness, enhancing immunologic function.
Polyporus (edema-alleviating diuretic): inducing diuresis to remove edema, eliminating dampness by diuresis, diuretic effect is stronger, and diuresis mechanism is to suppress renal tubules to water and electrolytical heavy absorption, also has Promote immunity and antibacterial action.
Rhizoma Alismatis (edema-alleviating diuretic): inducing diuresis to remove edema, eliminating dampness by diuresis, purges heat, and diuretic effect is stronger, can increase urine amount, has blood pressure lowering, hypoglycemic activity.
Semen Plantaginis (stranguria-relieving diuretic): inducing diuresis for treating stranguria syndrome, eliminating dampness by diuresis antidiarrheal, improving eyesight, eliminates the phlegm, and kind tonneau water channel, all has inhibitory action to various bacillus and staphylococcus.
Be used for the treatment of the Chinese medicine preparation of central serous chorioretinopathy, the adjuvant that described Chinese medicine preparation contains active component and pharmaceutically allows, described active component is described Chinese medicine composition or the extract of described Chinese medicine composition.
Improve as one, the described adjuvant pharmaceutically allowing comprises: sucrose and dextrin.
As improving further, the described adjuvant pharmaceutically allowing also comprises Mel.
As improving further, the dosage form of described Chinese medicine preparation is tablet, granule, decoction, capsule or pill.
Instructions of taking: above-mentioned granule, boiling water rushes to 250ml, and pill, capsule, decoction or tablet are directly taken, and take every day 1 time, 10 days 1 courses for the treatment of, can take continuously 2 courses for the treatment of.The irritable foods such as period in a medicine taboo is pungent, wine.
Owing to having adopted technique scheme, the invention has the beneficial effects as follows:
The present invention adopts rational formula, the Radix Astragali in Chinese medicine composition composition formula and Rhizoma Alismatis are monarch drug, Radix Codonopsis, Polyporus and Poria are ministerial drug, the Rhizoma Atractylodis Macrocephalae, Semen Plantaginis, Radix Angelicae Sinensis, Radix Rehmanniae Preparata, Radix Paeoniae Rubra, Ramulus Cinnamomi, Herba Asari is adjuvant drug, Radix Glycyrrhizae is for making medicine, Radix Codonopsis, the Radix Astragali, the Rhizoma Atractylodis Macrocephalae, Radix Glycyrrhizae Radix Rehmanniae Preparata, Radix Angelicae Sinensis, the Qi-tonifying drugs such as Radix Paeoniae Rubra, hematonic is qi-restoratives medicine, this class medicine can reinforcing body resistance, tonification is precise and tiny, can cure mainly human righteousness's weakness, the disease that cereal nutrient loss causes, use Qi-tonifying drug Chang Peiwu hematonic, form is that " tangible blood can not be spontaneous for what is called, be born in invisible gas ", blood being the material foundation of QI, blood deficiency gas without comply with, blood deficiency also can cause the deficiency of vital energy, therefore QI and blood is with mending enhancing body self-healing ability and resistance, Ramulus Cinnamomi, Herba Asari are diaphoretic medicines, and having dispelling exopathogens from superficies of the body, treatment table disease is main medicine, has inducing diuresis to remove edema, analgesia, sedation, with QI invigorating, hematonic compatibility, can reach the effect of strengthening vital QI to eliminate pathogenic factors, Polyporus, Poria, Rhizoma Alismatis, Semen Plantaginis are damp-clearing drugs, have tonneau water channel, and oozing sluices wets, and treatment retention of water-damp in the body disease, has diuresis, antipathogen, and some drugs regulates the effect of immunologic function in addition.
The Chinese medicine composition that the present invention is used for the treatment of central serous chorioretinopathy fill blood on basis, add with diaphoretic medicine reach dispelling exopathogens from superficies of the body, treatment table disease is main medicine, there is the effect of inducing diuresis to remove edema, analgesia, calmness, remove the cause of disease of patient's psychentonia, damp-clearing drug has tonneau water channel, oozing sluices wets, treatment retention of water-damp in the body disease, has diuresis, antipathogen, and some drugs regulates the effect of immunologic function in addition.Therefore can be effectively for disease, the object that reaches fast, effectively treats.Therefore, in the time of central serous chorioretinopathy, can obviously shorten treatment cycle, make fast patient recover vision, alleviate patient's misery, and reduce the generation of other complication.
The specific embodiment
In order to make object of the present invention, technical scheme and advantage clearer, below in conjunction with embodiment, the present invention is further elaborated.Should be appreciated that specific embodiment described herein, only in order to explain the present invention, is not intended to limit the present invention.
Embodiment mono-
Be used for the treatment of the Chinese medicine composition of central serous chorioretinopathy, comprise following crude drug: Radix Codonopsis 9g, Radix Astragali 9g, Rhizoma Atractylodis Macrocephalae 9g, Radix Rehmanniae Preparata 9g, Radix Angelicae Sinensis 9g, Radix Paeoniae Rubra 9g, Polyporus 9g, Poria 9g, Rhizoma Alismatis 9g, Semen Plantaginis 9g, Ramulus Cinnamomi 9g, Herba Asari 3g.
Embodiment bis-
Be used for the treatment of the Chinese medicine composition of central serous chorioretinopathy, comprise following crude drug: Radix Codonopsis 10g, Radix Astragali 10g, Rhizoma Atractylodis Macrocephalae 10g, Radix Glycyrrhizae 3g, Radix Rehmanniae Preparata 10g, Radix Angelicae Sinensis 10g, Radix Paeoniae Rubra 10g, Polyporus 10g, Poria 10g, Rhizoma Alismatis 10g, Semen Plantaginis 10g, Ramulus Cinnamomi 10g, Herba Asari 4g.
Embodiment tri-
Be used for the treatment of the Chinese medicine composition of central serous chorioretinopathy, comprise following crude drug: Radix Codonopsis 12g, Radix Astragali 12g, Rhizoma Atractylodis Macrocephalae 12g, Radix Glycyrrhizae 3g, Radix Rehmanniae Preparata 12g, Radix Angelicae Sinensis 12g, Radix Paeoniae Rubra 12g, Polyporus 12g, Poria 12g, Rhizoma Alismatis 12g, Semen Plantaginis 12g, Ramulus Cinnamomi 12g, Herba Asari 6g.
Embodiment tetra-
Be used for the treatment of the Chinese medicine composition of central serous chorioretinopathy, comprise following crude drug: Radix Codonopsis 10g, Radix Astragali 10g, Rhizoma Atractylodis Macrocephalae 11g, Radix Glycyrrhizae 3g, Radix Rehmanniae Preparata 10g, Radix Angelicae Sinensis 10g, Radix Paeoniae Rubra 8g, Polyporus 11g, Poria 12g, Rhizoma Alismatis 10g, Semen Plantaginis 12g, Ramulus Cinnamomi 11g, Herba Asari 5g.
Embodiment five
Be used for the treatment of the Chinese medicine composition of central serous chorioretinopathy, comprise following crude drug: Radix Codonopsis 9g, Radix Astragali 9g, Rhizoma Atractylodis Macrocephalae 9g, Radix Glycyrrhizae 3g, Radix Rehmanniae Preparata 9g, Radix Angelicae Sinensis 10g, Radix Paeoniae Rubra 9g, Polyporus 6g, Poria 6g, Rhizoma Alismatis 9g, Semen Plantaginis 9g, Ramulus Cinnamomi 9g, Herba Asari 6g.
Embodiment six
Be used for the treatment of the Chinese medicine preparation of central serous chorioretinopathy, the adjuvant that described Chinese medicine preparation contains active component and pharmaceutically allows, described active component is the Chinese medicine composition in above-described embodiment one, in Chinese medicine composition in embodiment mono-, add medical cane sugar powder and medicinal dextrin, granulate, must be used for the Chinese medicine granules of central serous chorioretinopathy.
Embodiment seven
Be used for the treatment of the Chinese medicine preparation of central serous chorioretinopathy, the adjuvant that described Chinese medicine preparation contains active component and pharmaceutically allows, described active component is the extract of the Chinese medicine composition in above-described embodiment two, in described extract, add medical cane sugar powder, medicinal dextrin and Mel, pill, must be used for the medicine pill of central serous chorioretinopathy.
Embodiment eight
Be used for the treatment of the Chinese medicine preparation of central serous chorioretinopathy, the adjuvant that described Chinese medicine preparation contains active component and pharmaceutically allows, described active component is the extract of the Chinese medicine composition in above-described embodiment three, in described extract, add medical cane sugar powder, medicinal dextrin, tabletting, must be used for the Chinese medicinal tablet of central serous chorioretinopathy.
Embodiment nine
Be used for the treatment of the Chinese medicine preparation of central serous chorioretinopathy, the adjuvant that described Chinese medicine preparation contains active component and pharmaceutically allows, described active component is the extracting solution after the Chinese medicine composition in above-described embodiment four decocts with water, in described extracting solution, add medical cane sugar powder, medicinal dextrin, mix, must be used for the Chinese medicine decoction of central serous chorioretinopathy.
Case 1
Patient Zhang, man, 43 years old, because right eye is dimmed depending on thing, distortion is examined for 1 week.Check: vision: right 0.6, left 1.0, right eye examination of ocular fundus shows that to look nipple border clear, and color is light red, macular area edema, reflective dizzy around, foveal reflex disappears.OCT checks and shows the shallow disengaging of macular area retina, is diagnosed as centrality serous detachment of retina.Treatment: adopt above-mentioned preparation oral, 1 time on the 1st, totally 10 days, observe OCT and change, continue application and observe OCT after 10 days and change, can see that detachment of retina calms down gradually, until finally return to one's perfect health.
Case 2
Patient Zhao, man, 39 years old, because right eye blurred vision is examined for 2 weeks.Check: vision: the right side 0.4, a left side 1.0, right eye examination of ocular fundus shows that central fovea of macula luminous reflectance disappears, and has reflective dizzy around.OCT diagnosis: centrality serous detachment of retina.Treatment: adopt above-mentioned preparation oral, 1 time on the 1st, totally 10 days, observe OCT, the hydrops under neuroepithelium of retina tails off gradually, continues application 10 days, and under neuroepithelium, hydrops absorbs completely, and retina calms down.
Case 3
Patient witch, man, 40 years old, because left eye blurring of vision was examined over 3 days.Check: vision: the right side 1.0, a left side 0.6, left eye examination of ocular fundus shows that central fovea of macula luminous reflectance disappears, and has reflective dizzy around.OCT diagnosis: centrality serous detachment of retina.Treatment: adopt above-mentioned preparation oral, 1 time on the 1st, totally 10 days, observe OCT, under neuroepithelium of retina, hydrops tails off as seen, continues oral 10 days, and under neuroepithelium, hydrops absorbs completely, and retina calms down.
Comparative example
60 routine central serous chorioretinopathy patients are tested, and wherein 30 examples are test group, and other 30 examples are matched group, and 30 of test group routine patients are taken to the present invention 20 days, within 20 days, observe afterwards the variation of OCT, and retina calms down substantially, recover normal; And do not take the present invention, do not do the routine patient of matched group 30 that treats, within 20 days, observe afterwards the variation of OCT, under neuroepithelium of retina, hydrops has no significant change, and retina is shallow disengaging still.
The foregoing is only preferred embodiment of the present invention, not in order to limit the present invention, all any modifications of doing within the spirit and principles in the present invention, be equal to and replace and improvement etc., within all should being included in protection scope of the present invention.
Claims (7)
1. be used for the treatment of the Chinese medicine composition of central serous chorioretinopathy, it is characterized in that described Chinese medicine composition is mainly made up of following raw material: Radix Codonopsis 9～12g, the Radix Astragali 9～12g, the Rhizoma Atractylodis Macrocephalae 9～12g, Radix Rehmanniae Preparata 9～12g, Radix Angelicae Sinensis 9～12g, Radix Paeoniae Rubra 9～12g, Polyporus 9～12g, Poria 9～12g, Rhizoma Alismatis 9～12g, Semen Plantaginis 9～12g, Ramulus Cinnamomi 9～12g and Herba Asari 3～6g.
2. the Chinese medicine composition that is used for the treatment of central serous chorioretinopathy as claimed in claim 1, is characterized in that described Chinese medicine composition is mainly made up of following raw material: Radix Codonopsis 9～12g, the Radix Astragali 9～12g, the Rhizoma Atractylodis Macrocephalae 9～12g, Radix Glycyrrhizae 2～3g, Radix Rehmanniae Preparata 9～12g, Radix Angelicae Sinensis 9～12g, Radix Paeoniae Rubra 9～12g, Polyporus 9～12g, Poria 9～12g, Rhizoma Alismatis 9～12g, Semen Plantaginis 9～12g, Ramulus Cinnamomi 9～12g, Herba Asari 3～6g and Radix Glycyrrhizae 2～3g.
3. the Chinese medicine composition that is used for the treatment of central serous chorioretinopathy as claimed in claim 2, is characterized in that described Chinese medicine composition is mainly made up of following raw material: Radix Codonopsis 10g, Radix Astragali 10g, Rhizoma Atractylodis Macrocephalae 10g, Radix Rehmanniae Preparata 10g, Radix Angelicae Sinensis 10g, Radix Paeoniae Rubra 10g, Polyporus 10g, Poria 10g, Rhizoma Alismatis 10g, Semen Plantaginis 10g, Ramulus Cinnamomi 10g, Herba Asari 4g and Radix Glycyrrhizae 3g.
4. be used for the treatment of the Chinese medicine preparation of central serous chorioretinopathy, it is characterized in that: the adjuvant that described Chinese medicine preparation contains active component and pharmaceutically allows, described active component is Chinese medicine composition described in claim 1,2 or 3 or the extract of described Chinese medicine composition.
5. the Chinese medicine preparation that is used for the treatment of central serous chorioretinopathy as claimed in claim 4, is characterized in that: the described adjuvant pharmaceutically allowing comprises: sucrose and dextrin.
6. the Chinese medicine preparation that is used for the treatment of central serous chorioretinopathy as claimed in claim 5, is characterized in that: the described adjuvant pharmaceutically allowing also comprises Mel.
7. the Chinese medicine preparation that is used for the treatment of central serous chorioretinopathy as claimed in claim 4, is characterized in that: the dosage form of described Chinese medicine preparation is tablet, granule, decoction, capsule or pill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410098468.9A CN103830453A (en) | 2014-03-17 | 2014-03-17 | Traditional Chinese medicine composition and traditional Chinese medicine preparation for treating central serous chorioretinopathy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410098468.9A CN103830453A (en) | 2014-03-17 | 2014-03-17 | Traditional Chinese medicine composition and traditional Chinese medicine preparation for treating central serous chorioretinopathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103830453A true CN103830453A (en) | 2014-06-04 |
Family
ID=50794555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410098468.9A Pending CN103830453A (en) | 2014-03-17 | 2014-03-17 | Traditional Chinese medicine composition and traditional Chinese medicine preparation for treating central serous chorioretinopathy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103830453A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105362524A (en) * | 2015-12-14 | 2016-03-02 | 青岛华仁太医药业有限公司 | Traditional Chinese medicine composition for treating retinitis and preparation method of traditional Chinese medicine composition |
| CN111494585A (en) * | 2020-05-06 | 2020-08-07 | 任秋生 | Traditional Chinese medicine composition and application thereof in treating polypoid choroidal vasculopathy |
| CN112656902A (en) * | 2020-10-16 | 2021-04-16 | 张铭连 | Dampness-removing granule formula for treating central serous chorioretinopathy |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102210841A (en) * | 2011-05-18 | 2011-10-12 | 刘永华 | Chinese medicinal preparation for treating central serous retinopathy |
| CN103623139A (en) * | 2012-08-25 | 2014-03-12 | 石家庄以岭药业股份有限公司 | Application of traditional Chinese medicine composition to prepare medicaments for treating central serous chorioretinopathy |
-
2014
- 2014-03-17 CN CN201410098468.9A patent/CN103830453A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102210841A (en) * | 2011-05-18 | 2011-10-12 | 刘永华 | Chinese medicinal preparation for treating central serous retinopathy |
| CN103623139A (en) * | 2012-08-25 | 2014-03-12 | 石家庄以岭药业股份有限公司 | Application of traditional Chinese medicine composition to prepare medicaments for treating central serous chorioretinopathy |
Non-Patent Citations (4)
| Title |
|---|
| 周尚昆: "唐由之治疗中心性浆液性脉络膜视网膜病变经验", 《中国中医眼科杂志》, vol. 21, no. 01, 28 February 2011 (2011-02-28), pages 26 - 27 * |
| 李进: "五苓散加味治疗"中浆"26例疗效观察", 《河南中医药学刊》, vol. 10, no. 03, 20 May 1995 (1995-05-20), pages 19 - 20 * |
| 王桂红: "中心性浆液性脉络膜视网膜病变的中医治疗近况", 《河北中医》, vol. 23, no. 03, 28 March 2001 (2001-03-28), pages 237 - 239 * |
| 谷万章: "眼科常用中药杂记", 《航空航天医药》, vol. 15, no. 03, 25 September 2004 (2004-09-25), pages 185 - 187 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105362524A (en) * | 2015-12-14 | 2016-03-02 | 青岛华仁太医药业有限公司 | Traditional Chinese medicine composition for treating retinitis and preparation method of traditional Chinese medicine composition |
| CN111494585A (en) * | 2020-05-06 | 2020-08-07 | 任秋生 | Traditional Chinese medicine composition and application thereof in treating polypoid choroidal vasculopathy |
| CN112656902A (en) * | 2020-10-16 | 2021-04-16 | 张铭连 | Dampness-removing granule formula for treating central serous chorioretinopathy |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103341004B (en) | Chinese medicine composition for treating delayed menstrual cycle | |
| CN103830453A (en) | Traditional Chinese medicine composition and traditional Chinese medicine preparation for treating central serous chorioretinopathy | |
| CN101439170A (en) | Chinese medicine prescription for treating ulcerative colitis | |
| CN105079551A (en) | Traditional Chinese medicine composition for treating edema | |
| CN102416145A (en) | Traditional Chinese medicine composition for treating menstrual disorder | |
| CN103735788A (en) | Traditional Chinese medicine composition for treating edema | |
| CN104013806B (en) | A kind of Chinese prescription for being used to treat diabetes | |
| CN102210841B (en) | Chinese medicinal preparation for treating central serous retinopathy | |
| CN104587257A (en) | Traditional Chinese medicine composition for treating diabetic macular edema | |
| CN103705900A (en) | Traditional Chinese medicine composition for treating hypertension | |
| CN103251889A (en) | Traditional Chinese medicine composition for treating agalactia | |
| CN103041334B (en) | Traditional Chinese medicine composition for treating abdominal distension | |
| CN102631578B (en) | Method for preparing traditional Chinese medicine (TCM) lotion for treating edema type pustule on sole | |
| CN103816493B (en) | A kind of Chinese medicine composition treating instability of kidney QI | |
| CN103816469A (en) | Chinese medicinal composition for treating deficiency of spleen and kidneys | |
| CN102961696A (en) | Chinese medicinal composition for treating diabetic nephropathy edema | |
| CN103041333A (en) | Traditional Chinese medicine composition for treating gastritis | |
| CN104644916A (en) | Traditional Chinese medicine composition for treating hypertension | |
| CN105687899A (en) | Traditional Chinese medicine composition for treating senile plaques | |
| CN105797044A (en) | Traditional Chinese medicinal composition for treating gastric ulcer | |
| CN104491403A (en) | Medicine for treating central retinochoroiditis and preparation method | |
| CN104771739A (en) | Traditional Chinese medicine composition for treating climacteric syndrome | |
| CN105456832A (en) | Decoction medicine for treating infantile diarrhea and preparation method thereof | |
| CN104189603A (en) | Traditional Chinese medicine composition for treating vertigo | |
| CN104398847A (en) | Medicinal decoction for treating vitreous opacities and fundus hemorrhage and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140604 |
|
| RJ01 | Rejection of invention patent application after publication |